Impact of GLP-1 Receptor Agonists on Cardiorenal Outcomes in Obese Patients with Type 2 Diabetes and Stage 3 CKD

The trend in the increasing co-occurrence of type 2 diabetes mellitus, obesity and Chronic Kidney Disease (CKD) is a significant clinical dilemma because of the relational effects on cardiovascular and renal health. Stage 3 CKD patients are especially susceptible, as deteriorating kidney performance leads to a higher risk of adverse cardiorenal outcomes. Over the last few years, Glucagon-Like Peptide-1 (GLP-1) receptor agonists have proved to be promising therapeutic agents that have the potential to have beyond glycaemic control benefits. The paper will discuss the cardiovascular and renal outcomes in patients with type 2 diabetes and stage 3 CKD who are receiving GLP-1 receptor agonists. The databases utilized included Google Scholar and PubMed to carry out a systematic review of recent clinical trials and peer-reviewed studies. Data indicate that GLP-1 receptor agonists are likely to have a distinct role in major adverse cardiovascular events, such as myocardial infarction and stroke and provide protective renal function in terms of decreased albuminuria and a slower rate of decline in estimated Glomerular Filtration Rate (eGFR). The overall implications of the findings are that the GLP-1 receptor agonists can provide significant cardiorenal benefits to this high-risk patient population. Their inclusion in treatment approaches can enhance the approaches in the long term, though more studies are required before long-term safety and effectiveness can be guaranteed.